

A tissue-on-a-chip platform for systems-level studies of ALS pathology and drug screening

<https://www.neurodegenerationresearch.eu/survey/a-tissue-on-a-chip-platform-for-systems-level-studies-of-als-pathology-and-drug-screening/>

Name of Fellow

Institution

Funder

European Commission Horizon 2020

Contact information of fellow

Country

EC

Title of project/programme

A tissue-on-a-chip platform for systems-level studies of ALS pathology and drug screening

Source of funding information

European Commission Horizon 2020

Total sum awarded (Euro)

€ 164,653

Start date of award

30/09/15

Total duration of award in years

2.0

The project/programme is most relevant to:

Motor neurone diseases

Keywords

ALS | neurodegeneration | organs-on-a-chip | systems pharmacology | systems biology

Research Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease, which affects approximately 2 per 100000 people. Currently, there is no ALS treatment. The main tool for preclinical ALS studies is the hSOD1G93A mouse. However, despite promising results in this model, all candidate drugs failed in clinical trials. These failures have been partly attributed to

differences in the physiology of human and mice nerve cells, and the inability of the established drug design approach to block ALS pathology. There is urgent need for new tools that will complement this mouse model, improve understanding of ALS pathology, and suggest better leads for clinical trials. The objective of the proposed study is to develop a tissue-on-a-chip platform for systems-level studies of ALS pathology and drug screening. The system is built around a novel thin porous scaffold, where systems of normal or ALS-type mouse and human motor neurons will be cultured inside an appropriate 3D ECM analog, and their response (intracellular signaling, cell processes, cell-cell communication) to stimuli panels in the presence of drugs will be quantified via high-throughput proteomics and fluorescent imaging. Acquired data will be interpreted by modifications of state-of-the-art system biology tools. The outcomes of the proposed research can lead to new ALS treatments by identifying new drug targets (via mechanistic description of ALS pathology), and by developing better ways to evaluate candidate drugs before clinical trials (via comparing drug response in human and mouse cells). Results can be translated to other neurodegenerative diseases. Finally, the proposal offers an opportunity to a promising researcher to relocate from MIT to Greece, collaborate with a leading neurobiology lab in a world-class environment and a systems pharmacology SME, and translate his research via two startup companies. The host envisions the opportunity for a tenure-track faculty position for the experienced researcher.

Types:

Fellowships

Member States:

European Commission

Diseases:

Motor neurone diseases

Years:

2016

Database Categories:

N/A

Database Tags:

N/A